Nelson Dusetti: A major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer

Nelson Dusetti shared on LinkedIn:

“We are thrilled to announce a major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer, now extended to metastatic patients through fine needle aspiration (FNA) biopsies. This development broadens the application of the Pancreas View transcriptomic signature, initially validated in operable patients, to include all pancreatic cancer patients, marking a significant step toward more personalized and effective treatments.”

Source: Nelson Dusetti/LinkedIn

More posts featuring Nelson Dusetti on oncodaily.com

Nelson Dusetti is Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.